Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAB-301

Plasma-derived product · Immune activation, directed at MERS-CoV spike protein

Phase 1 Most advanced trial (none active)
1 Registered trials

What is SAB-301?

SAB-301 is a purified human immune globulin G polyclonal antibody that specifically binds the MERS-CoV spike (S) protein, the viral membrane component responsible for attachment to host cells. It is purified from the plasma of immunized transchromosomic bovines and is studied in Middle East Respiratory Syndrome coronavirus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Targets
MERS-CoV spike protein
Mechanism
Immune activation, directed at MERS-CoV spike protein
Therapy area
Infectious disease
In trials of
SABS
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
3VR9NL86WG

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02788188 Phase 1 Middle East Respiratory Syndrome Coronavirus Completed SABS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Middle East Respiratory Syndrome Coronavirus

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.